Matthew Gline, CEO at Roivant Sciences Ltd. (ROIV), sold 184,648 shares at $5.52 ($1.0M) on 2022-03-07, disclosed to the SEC on 2022-03-09.
Open-market sale of $1.0M ROIV by CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $5.52 | 92,324 | $510K | 50.0% |
| 2 | $5.52 | 92,324 | $510K | 50.0% |
| Total | $5.52 avg | 184,648 | $1.0M | 100% |
| Filing → |
| ROIV | BUY | 2025-09-18 | $50K | — | Filing → |
| ROIV | SELL | 2024-09-24 | $46.8M | — | Filing → |
| ROIV | SELL | 2022-10-27 | $170K | — | Filing → |